Ex vivo therapeutic screening of metastatic cSCC: A review of methodological considerations for clinical implementation
Open Access
- 24 April 2024
- journal article
- review article
- Published by Wiley in Experimental Dermatology
- Vol. 33 (4) , e15089
Abstract
Cutaneous squamous cell carcinoma (cSCC) is the second most common malignancy worldwide, with most deaths caused by locally advanced and metastatic disease. Treatment of resectable metastases is typically limited to invasive surgery with adjuvant radiotherapy; however, many patients fail to respond and there is minimal data to predict response or propose effective alternatives. Precision medicine could improve this, though genomic biomarkers remain elusive in the high mutational background and genomic complexity of cSCC. A phenotypic approach to precision medicine using patient‐derived ex vivo tumour models is gaining favour for its capacity to directly assess biological responses to therapeutics as a functional, predictive biomarker. However, the use of ex vivo models for guiding therapeutic selection has yet to be employed for metastatic cSCC. This review will therefore evaluate the existing experimental models of metastatic cSCC and discuss how ex vivo methods could overcome the shortcomings of these existing models. Disease‐specific considerations for a prospective methodological pipeline will also be discussed in the context of precision medicine.Keywords
Funding Information
- National Health and Medical Research Council
This publication has 83 references indexed in Scilit:
- Bioengineered hydrogels enhance ex vivo preservation of patient-derived tumor explants for drug evaluationBiomaterials, 2024
- Making In Vitro Tumor Models Whole AgainAdvanced Healthcare Materials, 2023
- Cutaneous Squamous Cell Carcinoma in Immunosuppressed PatientsCurrent Oncology Reports, 2019
- A patient‐derived explant (PDE) model of hormone‐dependent cancerMolecular Oncology, 2018
- Reviewing the genetic alterations in high‐risk cutaneous squamous cell carcinoma: A search for prognostic markers and therapeutic targetsHead & Neck, 2017
- Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United StatesJAMA Dermatology, 2017
- The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factorsJournal of Surgical Oncology, 2012
- Serpin Peptidase Inhibitor Clade A Member 1 (SerpinA1) Is a Novel Biomarker for Progression of Cutaneous Squamous Cell CarcinomaThe American Journal of Pathology, 2011
- Polyhydroxylated fatty alcohols derived from avocado suppress inflammatory response and provide non-sunscreen protection against UV-induced damage in skin cellsArchives of Dermatological Research, 2010
- Comparison of cellular radiosensitivity between different localizations of head and neck squamous-cell carcinomaJournal of Cancer Research and Clinical Oncology, 1995